Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Net Cash Flow (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Net Cash Flow for 6 consecutive years, with -$8.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 69.83% to -$8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$41.7 million, a 108.14% decrease, with the full-year FY2025 number at -$41.1 million, down 104.88% from a year prior.
  • Net Cash Flow was -$8.5 million for Q4 2025 at Relay Therapeutics, up from -$22.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $246.9 million in Q3 2022 to a low of -$202.8 million in Q4 2022.
  • A 5-year average of -$18.2 million and a median of -$10.1 million in 2022 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 883.58% in 2022; the steepest drop was 1131.23% in 2022.
  • Relay Therapeutics' Net Cash Flow stood at $51.6 million in 2021, then tumbled by 493.42% to -$202.8 million in 2022, then skyrocketed by 96.26% to -$7.6 million in 2023, then tumbled by 269.73% to -$28.1 million in 2024, then skyrocketed by 69.83% to -$8.5 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Net Cash Flow are -$8.5 million (Q4 2025), -$22.4 million (Q3 2025), and $19.9 million (Q2 2025).